Abstract Library

#4474 Follow-up 68Ga-DOTATATE PET/CT post resection of small bowel neuroendocrine neoplasia

Introduction: Surgery remains the mainstay of treatment for resectable neuroendocrine neoplasms (NENs). Post resection, guidelines suggest a risk-based approach to surveillance, with 3-6 monthly imaging based on tumour biology. However, there is a paucity of data regarding the timing of surveillance imaging for resected well-differentiated NEN.

Conference:

Presenting Author:

Authors: Sabahi Z, Chan D, Darbhamulla S, Mok C, Samra J,

Keywords: Neuroendocrine, 68Ga-DOTATATE PET/CT, Small bowel,

#4421 Head-to-head comparison of 18F-AlF-NOTA-JR11 PET/MR and 68Ga-DOTATATE PET/CT in patients with neuroendocrine tumours: A prospective study

Introduction: PET/MR combines the molecular advantages of PET with excellent morphologic and anatomic delineation of MRI.18F-AlF-NOTA-JR11, a novel SSTR antagonist with a high affinity for SSTR2, has the potential to perform better than SSTR agonists in neuroendocrine tumour imaging.

Conference:

Presenting Author: Yu J

Authors: Jin X, Xie Q, Lu M, Li J, Yang Z,

Keywords: neuroendocrine tumour, PET/MR, SSTR antagonist, 18F-AlF-NOTA-JR11,

#4033 Routine early 68Ga-DOTATATE PET/CT has low diagnostic yield after resection of pancreatic neuroendocrine neoplasms

Introduction: Following resection of primary pancreatic neuroendocrine neoplasm (P-NEN), the reported median disease free survival is ≥4y. 68Ga-DOTATATE PET/CT (DOTA-PET) is widely used for restaging following surgical resection of P-NEN due to a higher sensitivity compared to cross-sectional imaging. We hypothesized that early DOTA-PET has a low yield in detecting recurrent/residual or distant disease in patients following curative-intent surgical resection of non-metastatic localised P-NEN.

Conference:

Presenting Author:

Authors: Singh A, Chan D, Samra J, Pavlakis N, Engel A,

Keywords: Pancreatic NEN, post-resection, restaging, early 68Ga-DOTATATE PET/CT, diagnostic yield,

#3814 Intra-individual comparison of 68Ga-DOTATATE PET/CT and PET/MR

Introduction: Somatostatin receptor (SSTR) PET is a cornerstone of modern NET management and is used for (re)staging and PRRT selection. Next to PET/CT, hybrid PET/MR is now available for hybrid imaging of NETs.

Conference:

Presenting Author:

Authors: Ahmadi Bidakhvidi N, Lens G, Vandecaveye V, Grauwels S, Deckers W,

Keywords: 68Ga-DOTATATE, PET/CT, PET/MR,

#3681 18F-FDG PET/CT-avid discordant volume as a biomarker in patients with gastroenteropancreatic neuroendocrine neoplasms – A multicentre study

Introduction: Dual 18F-FDG and 68Ga-DOTATATE PET/CT is emerging as a powerful technique to predict tumor biology. Whilst the presence of discordant disease (FDG avid/DOTA non-avid) predicts poor prognosis, it remains unknown whether the volume of discordant disease is also a significant predictor.

Conference:

Presenting Author: Chan D

Authors: Chan D, Hayes A, Karfis I, Conner A, Mileva M,

Keywords: prognostic biomarker, PET imaging, 18F-FDG, 68Ga-DOTATATE, dual PET, discordance,